Literature DB >> 8314961

Premature luteinization is not eliminated by pituitary desensitization with leuprolide acetate in women undergoing gonadotrophin stimulation who demonstrated premature luteinization in a prior gonadotrophin-only cycle.

G E Hofmann1, P A Bergh, I Guzman, S Masuku, D Navot.   

Abstract

A total of 40 women who demonstrated premature luteinization (serum progesterone > or = 3.5 nmol/l (1.1 ng/ml) on or before the day of human chorionic gonadotrophin (HCG) administration) during ovarian stimulation with human menopausal gonadotrophins (HMG) were restimulated in 46 subsequent cycles after pituitary desensitization with the gonadotrophin-releasing hormone agonist (GnRHa, 1 mg), leuprolide acetate. Five women were treated with a double dose of agonist (2 mg) when premature luteinization was determined on the single dose protocol. In HMG-only cycles, a frank luteinizing hormone (LH) surge was detected in 30 cycles; 15 cycles were cancelled because of premature ovulation. In agonist cycles there were no cancellations, although 25 cycles demonstrated premature luteinization and in six cycles a frank LH surge was detected. Doubling the dose of the agonist did not prevent premature luteinization. Agonist cycles with and without premature luteinization did not differ in any in-vitro fertilization (IVF) outcome parameters (ampoules of gonadotrophins, day of HCG administration, peak oestradiol concentration, number of oocytes retrieved, fertilized, transferred or cryopreserved). We conclude that in patients who demonstrate premature luteinization in a gonadotrophin-only cycle, pituitary desensitization may not completely eliminate subtle luteinization or a frank LH surge.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314961     DOI: 10.1093/oxfordjournals.humrep.a138122

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  "Premature luteinization" in the era of GnRH analogue protocols: time to reconsider.

Authors:  Johnny S Younis
Journal:  J Assist Reprod Genet       Date:  2011-05-26       Impact factor: 3.412

Review 2.  The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization.

Authors:  B C Tarlatzis; G Grimbizis
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

3.  Osteopontin and Integrin αvβ3 Expression during the Implantation Window in IVF Patients with Elevated Serum Progesterone and Oestradiol Level.

Authors:  Z He; Y Ma; L Li; J Liu; H Yang; C Chen; N Lin; Y Bai; R Ma; R Li; Z Wu; J Qiao
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-06       Impact factor: 2.915

Review 4.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

5.  The Impact of Progesterone Level on Day Of hCG Injection in IVF Cycles on Clinical Pregnancy Rate.

Authors:  Jawa Ashmita; Swarankar Vikas; Garg Swati
Journal:  J Hum Reprod Sci       Date:  2017 Oct-Dec

6.  Systematic Analysis of Long Noncoding RNA and mRNA in Granulosa Cells during the Hen Ovulatory Cycle.

Authors:  Liang Li; Xun Deng; Silu Hu; Zhifu Cui; Zifan Ning; Taotao Gui; Xiaoling Zhao; Diyan Li; Yan Wang; Huadong Yin; Lin Ye; Yaofu Tian; Yao Zhang; Hua Li; Qing Zhu
Journal:  Animals (Basel)       Date:  2021-05-25       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.